Plastic waste is becoming an increasing problem, with 50 million tonnes of single-use plastic being produced each year.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...

Presented in vivo and in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the ...

Fully automated “self-driving” process development labs are an attractive idea, but human expertise and oversight will always be needed.

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 ...

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness -CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed indust ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

Organoids, assembloids, and organ-on-a-chip technologies represent transformative advances in the fields of drug discovery, precision medicine, and ...

Day One Biopharmaceuticals stock remains a "Strong Buy." Learn more about its outlook, surging revenue, and ADC pipeline ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

President Trump, in a rally-like speech in Kentucky, stressed familiar talking points on the economy, highlighting tax cuts ...